Inhibitex Merges With FermaVir As Part Of Strategic Transformation
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition will give Inhibitex access to FermaVir’s early-stage antiviral pipeline, including a potential herpes zoster infection treatment.